Clinical data

Betaglue Therapeutics is committed to pursue as lead indication Pancreatic Adenocarcinoma cancer, considering PDAC has one of the worst forms of cancer in terms of progression-free and overall survival and is the seventh most common cause of cancer related death worldwide. Around thirty percent of PDAC patients are considered as locally advanced cancer patients.

BetaGlue Therapeutics successfully completed all preclinical studies for this indication and started an Early Feasibility Study (EFS) in pancreatic cancer patients in Q1 2026.

YntraDose (previously called BAT-90) has been studied in a FIH Trial to assess the performance of BAT-90 during the percutaneous ablative procedure of resectable and unresectable primary liver lesions (HCC).

The study indicated that No treatment related AEs and ADEs limiting the ability to deploy YntraDose occurred and 100% of the lesions treated showed to have been reached by the product.

YntraDose (previously called BAT-90) has been studied also as treatment for radio-ablation of surgical margins following resection of breast tumoral lesions Stage 0/1/2A of DCIS (ductal carcinoma in situ) in a First in Human clinical investigation.

The formal Data monitoring committee (DMC) held confirmed the safety profile of the treatment indicating that the device demonstrated an acceptable acute safety profile with no serious adverse events/serious adverse device effects during the follow-up period.